Description
The ProbeSeq Cardiac Troponin I (cTnI) Aptamer is a high-affinity single-stranded DNA (ssDNA) molecular recognition element engineered for selective binding to human cardiac Troponin I, a regulatory protein released into circulation following cardiomyocyte injury. This product supports research-use biosensing and diagnostic assay development applications, including myocardial infarction biomarker detection, acute coronary syndrome studies, and integration into rapid cardiac diagnostic platforms.
Cardiac Troponin I is a component of the troponin complex that regulates calcium-mediated cardiac muscle contraction and is highly specific to cardiac tissue. Elevated circulating cTnI levels are strongly associated with myocardial injury and are widely used as a gold-standard biomarker in cardiovascular research and clinical diagnostics development. Sensitive detection of cTnI is critical for early-stage myocardial injury studies, disease progression monitoring, and development of rapid point-of-care cardiac testing technologies.
This aptamer provides selective molecular recognition of cTnI through sequence-defined binding interactions that support high target specificity and strong binding affinity under physiologically relevant conditions. Compared with antibody-based recognition elements, aptamers offer improved chemical stability, reproducible synthesis, and compatibility with surface functionalization strategies commonly used in electrochemical sensing, microfluidic systems, and lab-on-chip diagnostic devices.
The aptamer sequence is optimized to minimize non-specific adsorption, support stable immobilization on conductive and polymeric surfaces, and maintain binding performance across diverse buffer environments. These design features enable reliable integration into biosensor development workflows, diagnostic assay prototyping, and translational research platforms.
This product supports research programs focused on cardiovascular diagnostics, biosensor engineering, and advanced cardiac biomarker detection technologies.
What’s Included
Each product contains:
-
High-affinity ssDNA aptamer targeting human cardiac Troponin I
-
Sequence documentation for research traceability
-
Reconstitution guidelines and handling instructions
Custom sequence modifications, surface-functionalized variants, and bulk quantities are available upon request.
Target Strategy
The aptamer is selected against human cardiac Troponin I to support:
-
High binding specificity to cardiac-specific troponin I isoforms
-
Minimal cross-reactivity with skeletal troponin proteins
-
Stable target recognition under physiological ionic conditions
-
Compatibility with electrode and surface immobilization chemistries
Target selection prioritizes sensitivity, assay robustness, and integration into biosensing platforms.
Product Format
Available in two configurations:
Lyophilized format
• Delivered dry for enhanced stability and long-term storage
• Reconstitute in nuclease-free water or preferred buffer
Solution format
• Supplied at defined stock concentration (e.g., 100 µM)
• Provided in nuclease-free water or TE buffer
Custom concentrations and modification options available upon request.
Performance Orientation
Designed for compatibility with:
-
Electrochemical aptamer-based biosensors
-
Impedance and voltammetric sensing platforms
-
Optical and fluorescence-based detection systems
-
Surface immobilization and functionalization workflows
-
Microfluidic and lab-on-chip diagnostic systems
-
Point-of-care cardiac testing device development
Performance characteristics depend on assay configuration, surface chemistry, and experimental conditions.
Quality Control
Each batch undergoes:
-
Sequence verification
-
Purity confirmation (HPLC purification)
-
Concentration validation
-
Manufacturing quality control review
Certificate of Analysis (CoA) available upon request.
Applications
-
Myocardial infarction biomarker detection research
-
Acute coronary syndrome studies
-
Cardiovascular disease monitoring research
-
Electrochemical biosensor development
-
Diagnostic assay development and validation
-
Microfluidic and point-of-care cardiac platform integration
Storage
Store at –20 °C.
Lyophilized aptamers are stable for up to 12 months under recommended storage conditions. Avoid repeated freeze–thaw cycles for solution format.
